2,828 reports of this reaction
2.6% of all METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, manufactured by AiPing Pharmaceutical, Inc.. There are 2,828 FDA adverse event reports linking METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS to FATIGUE. This represents approximately 2.6% of all 106,995 adverse event reports for this drug.
Patients taking METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,828 FDA reports for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.6% of all adverse event reports for METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, making it a notable side effect.
If you experience fatigue while taking METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.